Literature DB >> 10334352

Radiation complications and tumor control after plaque radiotherapy of choroidal melanoma with macular involvement.

K Gündüz1, C L Shields, J A Shields, J Cater, J E Freire, L W Brady.   

Abstract

PURPOSE: To determine the outcome of plaque radiotherapy in the treatment of macular choroidal melanoma and to identify the risk factors associated with the development of radiation complications, tumor recurrence, and metastasis.
METHODS: Chart analysis of 630 consecutive patients (630 eyes) with macular choroidal melanoma managed by plaque radiotherapy between July 1976 and June 1992.
RESULTS: The median largest basal tumor diameter was 10 mm, and the median tumor thickness was 4 mm. By means of Kaplan-Meier estimates, visually significant maculopathy developed at 5 years in 40% of the patients, cataract in 32%, papillopathy in 13%, and tumor recurrence in 9%. Vision decrease by 3 or more Snellen lines was found in 40% of the patients at 5 years. Sixty-nine eyes (11%) were enucleated because of radiation complications and recurrence. Twelve percent of the patients developed metastasis by 5 years and 22% by 10 years. Results of multivariate Cox proportional hazards analyses showed that the significant predictors for tumor recurrence were a distance of tumor margin from the optic disk of less than 2 mm (P = .003) and retinal invasion (P = .009). The significant variables that were predictive of metastasis included tumor thickness greater than 4 mm (P = .02) and largest basal tumor diameter greater than 10 mm (P = .03).
CONCLUSIONS: Plaque radiotherapy offers a 91% 5-year local tumor control rate for macular choroidal melanoma. Despite good local tumor control, the risk for metastasis is 12% at 5 years and 22% at 10 years. In 11% of the patients, enucleation eventually became necessary because of radiation complications and tumor recurrence.

Entities:  

Mesh:

Year:  1999        PMID: 10334352     DOI: 10.1016/s0002-9394(98)00445-0

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  21 in total

1.  Transscleral local resection versus iodine brachytherapy for uveal melanomas that are large because of tumour height.

Authors:  Ilkka Puusaari; Bertil Damato; Tero Kivelä
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-11-18       Impact factor: 3.117

2.  Monte Carlo Simulation of the Treatment of Eye Tumors with (106)Ru Plaques: A Study on Maximum Tumor Height and Eccentric Placement.

Authors:  Lorenzo Brualla; Francisco J Zaragoza; Wolfgang Sauerwein
Journal:  Ocul Oncol Pathol       Date:  2014-05-07

3.  Ruthenium-106 plaque radiotherapy alone or in combination with transpupillary thermotherapy in the management of choroidal melanoma.

Authors:  Kaan Gündüz; Rengin Aslihan Kurt; Hale Elif Akmeşe; Kenan Köse; Omür Uçakhan-Gündüz
Journal:  Jpn J Ophthalmol       Date:  2010-08-11       Impact factor: 2.447

4.  Eccentric ruthenium plaque radiotherapy of posterior choroidal melanoma.

Authors:  Andrea Russo; Michela Laguardia; Bertil Damato
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-02-23       Impact factor: 3.117

5.  I-125 brachytherapy for choroidal melanoma photographic and angiographic abnormalities: the Collaborative Ocular Melanoma Study: COMS Report No. 30.

Authors:  H Culver Boldt; B Michele Melia; Judy C Liu; Sandra M Reynolds
Journal:  Ophthalmology       Date:  2009-01       Impact factor: 12.079

6.  Cataract development in patients treated with proton beam therapy for uveal melanoma.

Authors:  Ira Seibel; Dino Cordini; Annette Hager; Aline I Riechardt; Matus Rehak; Alexander Böker; Dirk Böhmer; Jens Heufelder; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-26       Impact factor: 3.117

7.  The Use of Intravitreal Anti-VEGF and Triamcinolone in the Treatment of Radiation Papillopathy.

Authors:  Kelsey Roelofs; Matthew P Larocque; Albert Murtha; Ezekiel Weis
Journal:  Ocul Oncol Pathol       Date:  2018-06-08

8.  Mechanisms of Optic Nerve Invasion in Primary Choroidal Melanoma.

Authors:  Eszter Szalai; Jill R Wells; Hans E Grossniklaus
Journal:  Ocul Oncol Pathol       Date:  2017-04-05

Review 9.  Local treatment failure after globe-conserving therapy for choroidal melanoma.

Authors:  Melinda Y Chang; Tara A McCannel
Journal:  Br J Ophthalmol       Date:  2013-05-03       Impact factor: 4.638

10.  Intravitreal bevacizumab combined with plaque brachytherapy reduces melanoma tumor volume and enhances resolution of exudative detachment.

Authors:  Samuel K Houston; Nisha V Shah; Christina Decatur; Marcela Lonngi; William Feuer; Arnold M Markoe; Timothy G Murray
Journal:  Clin Ophthalmol       Date:  2013-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.